CORDIS
EU research results

CORDIS

English EN
Translational Research Network in Prostate Cancer

Translational Research Network in Prostate Cancer

Objective

The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).

The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.

Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:

1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.

2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.

3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.

We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.

Coordinator

UNIVERSITY OF GLASGOW

Address

University Avenue
G12 8qq Glasgow

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 273 287,88

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 273 287,88

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 204 965,91

TURUN YLIOPISTO

Finland

EU Contribution

€ 269 145,36

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 255 374,28

MOSAIQUES DIAGNOSTICS GMBH

Germany

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 242 386,92

TAMPEREEN YLIOPISTO

Finland

TAMPEREEN KORKEAKOULUSAATIO SR

Finland

GenomeScan B.V.

Netherlands

EU Contribution

€ 319 217,85

ALMAC DIAGNOSTIC SERVICES LIMITED

United Kingdom

EU Contribution

€ 273 287,88

NUMARES AG

Germany

EU Contribution

€ 249 216,48

Partners (6)

Sort alphabetically

Expand all

UNIVERSITY OF STRATHCLYDE

Prostate Cancer UK

HELSINGIN YLIOPISTO

European Association of Urology

Carver Wilde Communications

CANCER RESEARCH UK LBG

Project information

Grant agreement ID: 721746

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 629 315,80

  • EU contribution

    € 2 629 315,80

Coordinated by:

UNIVERSITY OF GLASGOW

United Kingdom